Cover Image
市場調查報告書

PharmaPoint:急性冠狀動脈症候群--現在·未來市場參與企業

PharmaPoint: Acute Coronary Syndrome - Current and Future Players

出版商 GlobalData 商品編碼 314732
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:急性冠狀動脈症候群--現在·未來市場參與企業 PharmaPoint: Acute Coronary Syndrome - Current and Future Players
出版日期: 2014年07月31日 內容資訊: 英文 87 Pages
簡介

本報告提供急性冠狀動脈症候群(ACS)的全球市場現有·新加入企業之相關分析,提供您整體市場的未來展望和預期成長率,推動、阻礙市場要素,現在·未來的競爭趨勢,主要企業簡介(營業內容,策略,業績,SWOT分析),市場今後的方向性等調查、考察。

第1章 目錄

第2章 簡介

  • 分析的背景
  • 相關調查
  • 近日出版的相關調查

第3章 市場預測

  • 全球市場
    • 未來預測
    • 推動及阻礙市場要素:全球市場課題

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Amgen
    • AstraZeneca
    • Bristol-Myers Squibb
    • 第一三共
    • Eli Lilly
    • GlaxoSmithKline
    • Janssen Pharmaceuticals (Johnson & Johnson)
    • The Medicines Company
    • Merck & Co.
    • Pfizer
    • Sanofi

第5章 附錄

圖表一覽

目錄

GlobalData has released its pharma report, "PharmaPoint: Acute Coronary Syndrome - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing ACS Market. The report identifies and analyses the key companies shaping and driving the global ACS market. The report provides insight into the competitive ACS landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for ACS
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of ACS sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving ACS market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global ACS market landscape Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Amgen
    • 4.3.2. AstraZeneca
    • 4.3.3. Bristol-Myers Squibb
    • 4.3.4. Daiichi Sankyo
    • 4.3.5. Eli Lilly
    • 4.3.6. GlaxoSmithKline
    • 4.3.7. Janssen Pharmaceuticals (Johnson & Johnson)
    • 4.3.8. The Medicines Company
    • 4.3.9. Merck & Co.
    • 4.3.10. Pfizer
    • 4.3.11. Sanofi

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
    • 5.4.2. Diagnosed Acute Coronary Syndrome Patients
    • 5.4.3. Percent Drug-Treated Patients
    • 5.4.4. General Pricing Assumptions
    • 5.4.5. Generic Erosion
    • 5.4.6. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Authors
    • 5.6.1. Author
    • 5.6.2. Reviewer
    • 5.6.3. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($bn) for ACS, 2013-2023
  • Table 2: Acute Coronary Syndrome Market - Drivers and Barriers, 2014
  • Table 3: Key Companies in the Acute Coronary Syndrome Market, 2014
  • Table 4: Amgen's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 5: Amgen SWOT Analysis, 2014
  • Table 6: AstraZeneca's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 7: AstraZeneca SWOT Analysis, 2014
  • Table 8: Bristol-Myers Squibb's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 9: Bristol-Myers Squibb SWOT Analysis, 2014
  • Table 10: Daiichi Sankyo's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 11: Daiichi Sankyo SWOT Analysis, 2014
  • Table 12: Eli Lilly's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 13: Eli Lilly SWOT Analysis, 2014
  • Table 14: GlaxoSmithKline's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 15: GlaxoSmithKline SWOT Analysis, 2014
  • Table 16: Janssen's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 17: Janssen SWOT Analysis, 2014
  • Table 18: The Medicines Company's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 19: The Medicines Company SWOT Analysis, 2014
  • Table 20: Merck's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 21: Merck SWOT Analysis, 2014
  • Table 22: Pfizer's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 23: Pfizer SWOT Analysis, 2014
  • Table 24: Sanofi's Acute Coronary Syndrome Portfolio Assessment, 2014
  • Table 25: Sanofi SWOT Analysis, 2014
  • Table 26: Price Sources and Calculations, by Country
  • Table 27: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Acute Coronary Syndrome by Region, 2013-2023
  • Figure 2: Global* ACS Sales by Drug Class, 2013-2023
  • Figure 3: Global* Sales Forecast for PCSK9 mAbs, 2015-2023
  • Figure 4: Global* Sales Forecast of the New Antithrombotics, Xarelto and Zontivity, 2013-2023
  • Figure 5: Projected Global* Sales of ACS Drugs By Year, 2013-2023
  • Figure 6: Company Portfolio Gap Analysis in Acute Coronary Syndrome, 2013-2023
Back to Top